Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome. Pacritinib (SB1518) is a tyrosine kinase inhibitor (TKI) with equipotent activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256753/
https://www.ncbi.nlm.nih.gov/pubmed/22829080
http://dx.doi.org/10.1038/bcj.2011.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256753/
https://www.ncbi.nlm.nih.gov/pubmed/22829080
http://dx.doi.org/10.1038/bcj.2011.43

Ejemplares similares